Diagnosis and Treatment of Depression During Pregnancy
This free, CME-certified webinar helps you effectively screen for and treat depression during pregnancy. This is critical for your primary care practice if you see female patients during this important time. Depression affects up to 15% of women in the perinatal period. Yet it remains largely undertreated despite significant risks. The risks include higher exposure of the fetus to alcohol and drugs, less adequate prenatal care, higher rates of preeclampsia and low birth weight, and more. Many health care providers often have questions on antidepressant use. And patients can over-rely on information in media and social media that undervalues treatment. This webinar is presented by Project TEACH, a program funded by the New York State Office of Mental Health.
This program is intended for:
- Primary Care and Family Practice Physicians
- Nursing Professionals
- Other Mental Health, Primary Care and Pediatric Clinicians
At the end of this activity, participants should be able to:
- Review critical research findings in course of psychiatric disorder during pregnancy
- Provide treatment algorithm for management of psychiatric disorders during pregnancy
- Discuss reproductive safety of old and new psychiatric medications during pregnancy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
David H. Rubin, MD, reviewer
Jane Pimental, MPH
In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:
Lee S. Cohen, MD, speaker
Research Support for the National Pregnancy Registry for Atypical Antipsychotics: Alkermes Biopharmaceuticals, Forest/Actavis Pharmaceuticals, Otsuka Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Teva Pharmaceuticals
Other Research Support: Brain and Behavior Research Foundation, JayMac Pharmaceuticals, National Institute on Aging, National Institutes of Health, SAGE Therapeutics, Takeda/Lundbeck Pharmaceuticals
Consulting fee: Alkermes Biopharmaceuticals
All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit